Market Overview

UPDATE: Oppenheimer Downgrades Emerson to Perform on Lack of Catalysts to Growth

Related EMR
Barron's Recap: Trump's Disastrous Views On China
Must Watch Stocks for Today
Investing For Retirement: A Different Strategy For The $7 Million Portfolio (Seeking Alpha)

Oppenheimer reduced its rating on Emerson (NYSE: EMR) from Outperform to Perform and lowered its price target from $57 to $53.

Oppenheimer commented, "We are downgrading shares of EMR to Perform from Outperform, based on lack of high conviction catalysts to drive multiple expansion, and nearterm risk associated with exposure to capital spending. Initial guidance outlook for msd-hsd EPS growth appears a potentially more opportunistic backdrop for expectations, but does include a combined 17c headwind from pension and overlapping stock compensation plans (partially offset by ~6c favorable from lower restructuring spend, and material restructuring benefits)."

Emerson closed at $48.36 on Monday.

Latest Ratings for EMR

Nov 2015Societe GeneraleDowngradesBuyHold
Nov 2015Stifel NicolausMaintainsBuy
Oct 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for EMR
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (EMR)

Get Benzinga's Newsletters